Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01061749
Other study ID # NCI-2012-02912
Secondary ID NCI-2012-02912NA
Status Completed
Phase Phase 1
First received February 2, 2010
Last updated January 22, 2016
Start date November 2009
Est. completion date September 2014

Study information

Verified date December 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab in treating patients with advanced solid malignancies. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry [cancer/tumor]-killing substances to them.


Description:

PRIMARY OBJECTIVES:

I. Determine the safety and toxicity of the combination of AZD6244 and IMC-A12 in advanced solid tumors that have progressed on standard therapy.

II. Finding the maximum tolerated dose (MTD)/recommended phase II dose of the combination.

SECONDARY OBJECTIVES:

I. Explore preliminary evidence of efficacy of the combination of AZD6244 and IMC-A12 in advanced solid tumors using RECIST criteria for tumor response.

II. Define pharmacodynamic (PD) profile of the combination of IMC-A12 and AZD6244.

III. Correlate pharmacokinetics (PK) of the combination of IMC-A12 and AZD6244 to pharmacodynamic (PD) endpoints.

IV. Assess the PK/PD (phospho-S6) link with AZD6244 when administered in combination with IMC-A12.

OUTLINE: This is a dose-escalation study of selumetinib and cixutumumab.

Patients receive selumetinib orally (PO) twice daily (BID) on days 1-28 and cixutumumab intravenously (IV) on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2014
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist

- There is no limit on the number of prior treatment regimens

- Patients must be off prior chemotherapy, radiation therapy, hormonal therapy, or biological therapy for at least 4 weeks; patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy; patients with prostate cancer may continue to receive LHRH agonist (unless orchiectomy has been performed)

- ECOG performance status 0-1

- Life expectancy of greater than 3 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,200/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 mg/dL

- Albumin >= 2.5 g/dL

- Total bilirubin =< 1.5 X institutional upper limits of normal in the absence of Gilbert's syndrome

- AST(SGOT) and ALT(SGPT) =< 2.5 X institutional upper limit of normal

- Serum glucose =< 120 mg/dL

- Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45 mL/min for patients with creatinine levels above institutional normal.

- Patients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by CTEP Active Version of the CTCAE); chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis by the Principal Investigator

- As the effect of AZD6244 and IMC-A12 in combination on the developing human fetus is not known, women of child-bearing potential and men must agree to use adequate contraception (abstinence; hormonal or barrier method of birth control) for the study and at least 3 months after completion

- Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment

- Ability to understand and the willingness to sign a written informed consent document

- Measurable disease

- Patient must be able to swallow pills

- Patients must have LVEF > 45% before starting therapy as measured by echocardiogram or MUGA

- Patients should have a baseline ophthalmologic examination before starting therapy

Exclusion Criteria:

- Patient current evidence of active and uncontrolled infection, documented Child's class B-C cirrhosis, or active pancreatitis

- Uncontrolled hypertension (BP > 150/95 despite optimal therapy)

- Left ventricular ejection fraction of =< 45% or NYHA Class II-IV CHF

- Prior or current cardiomyopathy

- Atrial fibrillation with heart rate > 100 bpm

- Unstable ischemic heart disease (myocardial infarction within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly)

- Patients receiving any medications that are inhibitors or inducers of specific CYP450 enzyme(s) are ineligible

- History of growth hormone deficiency or excess, or patient is concurrently using growth hormone (GH), or growth hormone inhibitors

- Patient has a known hypersensitivity to the components of study drugs, its analogs, or drugs of similar chemical or biologic composition

- Patient has prior exposure to IGF-1R or RAF/MEK inhibitors

- The patient has poorly controlled diabetes mellitus, defined as a Hba1c > 7%

- Patients with active CNS metastases and/or carcinomatous meningitis are excluded; however, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 3 months prior to entry as defined as:

- No evidence of new or enlarging CNS metastasis

- No new signs or symptoms consistent with CNS metastasis

- Off steroids or on a stable dose of steroids for at least four weeks

- Patient with a primary central nervous system tumor

- Patient has known psychiatric or substance abuse disorders that is uncontrolled and would interfere with cooperation with the requirements of the trial

- Patient is pregnant or breastfeeding.

- Patient is Human Immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), as drug interactions between those agents and these experimental agents are wholly unknown; if this combination goes forward, this regimen will need to be tested in this group of patients in the future; patients with HIV who are well compensated and do not require HAART therapy are eligible for the study

- Patient has active hepatitis B or C on treatment

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy

- Use of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated with LHRH agonist at the time of trial entry

- Patients should avoid excessive sun exposure and use adequate sunscreen protection if sun exposure is anticipated

- History of any serious intraocular or retinal pathology as determined by the reference ophthalmologist, with the exception of controlled glaucoma or cataracts; in particular, patients with a history of retinal vein occlusion (RVC) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR as assessed by ophthalmic exam (e.g. evidence of new optic disc cupping, new visual field defects, intraocular pressure > 21 mmHg, uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes) must be excluded

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Cixutumumab
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Drug:
Selumetinib
Given PO

Locations

Country Name City State
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of selumetinib in combination with cixutumumab defined as the dose produced DLT in =< 1 out of 6 patients The proportion of patients with serious or life threatening toxicities will be estimated along with 95% confidence intervals. Tabulated by dose combination, by toxicity type, and by the severity. Up to 4 weeks Yes
Secondary Pharmacokinetics of the combination of selumetinib and cixutumumab Peak serum level (Cmax), the trough level (Cmin), and the Area Under the serum concentration time Curve (AUC) will be summarized using descriptive statistics. Prior to the dose and at 0.5, 1, 1.5, 2, 4, and 8 hours No
Secondary The proportion of patients who experience PR, CR, or SD as defined by RECIST criteria Up to 4 weeks after completion of study treatment No
See also
  Status Clinical Trial Phase
Withdrawn NCT01971489 - Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01093092 - Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Phase 1
Completed NCT01218620 - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00535119 - Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Phase 1
Completed NCT00070252 - Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Phase 1/Phase 2
Completed NCT02107443 - Improving Communication in Older Cancer Patients and Their Caregivers N/A
Completed NCT00608361 - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT00410553 - Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Phase 1
Completed NCT00499135 - Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors Phase 1
Completed NCT01625156 - Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery Phase 1
Completed NCT01154426 - ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT02116777 - Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Phase 1/Phase 2
Active, not recruiting NCT00878163 - GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Phase 1
Withdrawn NCT02627430 - Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Phase 1
Completed NCT01548482 - Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Active, not recruiting NCT01375829 - Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT00217373 - Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Phase 1
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT00045201 - Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors Phase 1